Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoarthritis of Hip Clear all
Completed Phase 3 Interventional

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

NCT00154219
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Lumiracoxib (drug)
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 4 Interventional Results available

3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty

NCT03948386
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
isobaric bupivacaine, hyperbaric bupivacaine, isobaric mepivacaine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 84 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Bensalem, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03304379
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Diclofenac, Celecoxib, Matching placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

NCT00325858
View directory record Official record
Conditions
Chronic Pain
Interventions
Tramadol HCl ER
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 23, 2026, 5:56 AM EDT
Terminated Phase 4 Interventional Results available

Trilogy AB Acetabular Hip System Post Approval Study

NCT00715026
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
Interventions
Trilogy AB Acetabular Hip Implant System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Two Year Study With Robotic-Arm Assisted Hip Surgery.

NCT03891199
View directory record Official record
Conditions
Surgery, Hip Osteoarthritis
Interventions
Robotic-Arm Assisted THA
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 23, 2026, 5:56 AM EDT
Enrolling by invitation Not applicable Interventional

G7 Freedom Constrained Vivacit-E Liners

NCT05587244
View directory record Official record
Conditions
Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures, Avascular Necrosis, Dislocation, Hip
Interventions
Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 5:56 AM EDT
Completed No phase listed Observational

A Clinical Investigation of the Taperloc® Microplasty™ Hip System

NCT00699309
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis
Interventions
Not listed
Lead sponsor
Biomet Orthopedics, LLC
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
4
States / cities
Beaufort, South Carolina • Greenville, South Carolina • Plano, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

NCT00314652
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 23, 2026, 5:56 AM EDT
Withdrawn Phase 2 Interventional

Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:

NCT02342977
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis
Interventions
Placebo, Lacosamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Jul 23, 2026, 5:56 AM EDT
Completed No phase listed Observational

A Clinical Investigation of the C2a-Taper™ Acetabular System

NCT00578851
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
Interventions
C2a - Taper™ Acetabular System
Device
Lead sponsor
Biomet Orthopedics, LLC
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Cedar Rapids, Iowa • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Jul 23, 2026, 5:56 AM EDT
Completed No phase listed Observational

Comparison of Muscle Atrophy After Direct Anterior & Posterior Total Hip Arthroplasty

NCT01636375
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jul 23, 2026, 5:56 AM EDT
Not listed Phase 1 Interventional

A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis

NCT04241354
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Degeneration
Interventions
Leukocyte-poor platelet rich plasma
Biological
Lead sponsor
Regenerative Orthopedics and Sports Medicine
Industry
Eligibility
30 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
North Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jul 23, 2026, 5:56 AM EDT
Not listed Not applicable Interventional

Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA

NCT00551967
View directory record Official record
Conditions
Osteoarthritis of Hip, Traumatic Arthritis of Hip
Interventions
Hip replacement
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Expectations in Subjects With Osteoarthritis

NCT02155257
View directory record Official record
Conditions
Osteoarthritis
Interventions
Modafinil, Gabapentin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Jul 23, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

NCT00973141
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 23, 2026, 5:56 AM EDT
Terminated Not applicable Interventional Results available

Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

NCT02161484
View directory record Official record
Conditions
Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
Interventions
Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%
Procedure · Drug
Lead sponsor
Rita Merman
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03161093
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

NCT02462850
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Jul 23, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 23, 2026, 5:56 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

NCT06792539
View directory record Official record
Conditions
Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Interventions
Polymotion Hip Resurfacing (PHR) System
Device
Lead sponsor
JointMedica Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 5:56 AM EDT
Not listed No phase listed Observational

Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem

NCT00951145
View directory record Official record
Conditions
Osteoarthritis of the Hip
Interventions
Not listed
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jul 23, 2026, 5:56 AM EDT